Canadian dermatology company Crescita Q3 revenue up 50% on manufacturing growth

Crescita Therapeutics

05/11/2025 12:37

Overview

Crescita Q3 2025 revenue rose 50% yr/yr, driven by Manufacturing segment growth

Company swung from a net loss to a net income of C$753, reflecting strong performance

Crescita repurchased 253,594 shares under NCIB, indicating financial confidence

Outlook

Crescita expects increased recurring revenue from a new 5-year supply agreement

Company exploring new partnerships for Pliaglis commercialization in various markets

Result Drivers

MANUFACTURING GROWTH - Co attributes revenue increase to significant order fulfillment and production volume ramp-up in Manufacturing segment

ASSET ACQUISITION - Acquisition of LPC assets, including Bacti Control brand, enhances recurring revenue and manufacturing capabilities

SUPPLY AGREEMENT - New five-year exclusive supply agreement strengthens Manufacturing segment with stable recurring revenues

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
C$5.39 mln
Q3 Adjusted EBITDA
C$262,000
Q3 Gross Margin
52.90%
Q3 Operating Expenses
C$3.01 mln
Q3 Operating Income
-C$162,000


Press Release: ID:nBw6DDVDSa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)